This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

GIOTRIF® (afatinib) is the first approved irreversible ErbB family blocker6

  • The ErbB family of receptors is composed of 4 members: EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB45
  • ErbB family members dimerise with other ErbB family members to signal5
  • EGFR mutations trigger aberrant ErbB family signalling, a key driver in the growth and spread of EGFR M+ NSCLC5
  • Whereas first-generation TKIs, such as gefitinib, reversibly inhibit EGFR, second-generation GIOTRIF® (afatinib) irreversibly blocks signalling from all ErbB family receptors5,7,8

EGFR M+= epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer.

GIOTRIF® (afatinib) has demonstrated consistent efficacy across multiple trials1-4

LUX-LUNG 3, 6 and 7 PFS results for GIOTRIF® in patients with common mutations (del19 or L858R)

  • Consistent efficacy demonstrated in 3 separate trials1-3

EGFR M+= epidermal growth factor receptor mutation positive; PFS=progression-free survival.

GIOTRIF® (afatinib) mechanism of action in NSCLC

GIOTRIF® (afatinib), an irreversible ErbB family blocker, inhibits signal transduction and blocks key pathways involved in cell growth and division. Since ErbB Family signalling can be initiated by a variety of homo- and heterodimers, a combined inhibition of more than one ErbB Family member may provide a more successful blockade of ErbB Family signalling.9

ErbB blockade mechanism of action

ErbB blockade mechanism of action

GIOTRIF® (afatinib) is a potent, oral, once-daily, highly selective, irreversible ErbB family blocker designed to covalently bind to and irreversibly block signaling from all homo- and heterodimers formed by ErbB Family receptors.5,10 Whereas reversible EGFR tyrosine kinase inhibitors (TKIs) only target EGFR, GIOTRIF® demonstrates activity against all the kinase-active members of the ErbB Family: EGFR, HER2 and ErbB4; and indirectly against ErbB3 by inhibiting its transphosphorylation by heterodimerisation partners. GIOTRIF® not only provides potent signal blockade of mutated EGFR, but also silences aberrant ErbB network activity and displays a long duration of action.5

You may be interested in:

Is this information compelling to you?

Request contact
from Boehringer Ingelheim

References

  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.
  3. Park K et al. Lancet Oncol. 2016;17(5):577-589.
  4. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.
  5. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.
  6. BI press release. www.boehringer-ingelheim.com. Accessed 19 December 2016.
  7. IRESSA® (gefitinib) Summary of Product Characteristics, 2014.
  8. TARCEVA® (erlotinib) Summary of Product Characteristics, 2014.
  9. Reid A et al. Eur J Cancer. 2007;43:481–9.
  10. Li D et al. Oncogene. 2008;27:4702–11.
  11. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.
  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.

  12. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top